Payment overview · 2025
General Payments
$1,938.85
113 reported records · 22 companies
Healthcare provider profile · identity verified
George A Evans, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SHEFFIELD, AL · NPI 1124073788
Verified facts
What the public records show
CMS Open Payments records show George A Evans, M.D. received $1,938.85 in general payments during 2025 across 113 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Relistor, Trintellix, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Relistor by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $426.93 | 22.0% | 18 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $243.48 | 12.6% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $236.71 | 12.2% | 31 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $149.31 | 7.7% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $138.53 | 7.1% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $124.93 | 6.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $113.67 | 5.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.93 | 4.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.02 | 3.4% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.62 | 2.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.06 | 2.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.69 | 1.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.68 | 1.5% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $29.25 | 1.5% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $29.24 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.88 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.77 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.76 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.63 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.82 | 0.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.81 | 0.8% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $14.13 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,938.85 | 113 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $250.58 | 8 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $201.99 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $182.05 | 25 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $178.18 | 24 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $157.03 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $138.53 | 6 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $124.93 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $124.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $115.50 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $113.67 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $111.53 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.93 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $90.93 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.26 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.62 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.06 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.53 | 5 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $29.24 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
236 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2300 | 231 |
| Zolpidem Tartrate | Zolpidem Tartrate | 1009 | 121 |
| Gabapentin | Gabapentin | 927 | 122 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 749 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 658 | 170 |
| Tramadol Hcl | Tramadol Hcl | 551 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 532 | 156 |
| Omeprazole | Omeprazole | 509 | 119 |
| Pregabalin | Pregabalin | 414 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 404 | 63 |
| Losartan Potassium | Losartan Potassium | 386 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 88 |
| Furosemide | Furosemide | 370 | 96 |
| Montelukast Sodium | Montelukast Sodium | 367 | 67 |
| Alprazolam | Alprazolam | 346 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 305 | 79 |
| Metformin Hcl | Metformin Hcl | 291 | 82 |
| Ezetimibe | Ezetimibe | 278 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 274 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 65 |
| Potassium Chloride | Potassium Chloride | 244 | 66 |
| Mounjaro | Tirzepatide | 236 | 40 |
| Ibuprofen | Ibuprofen | 223 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 212 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 197 | 41 |
| Lisinopril | Lisinopril | 196 | 52 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 192 | 21 |
| Trazodone Hcl | Trazodone Hcl | 185 | 51 |
| Fenofibrate | Fenofibrate | 173 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 41 |
| Clonazepam | Clonazepam | 159 | 19 |
| Celecoxib | Celecoxib | 157 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 157 | 39 |
| Jardiance | Empagliflozin | 157 | 32 |
| Buspirone Hcl | Buspirone Hcl | 156 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 155 | 32 |
| Promethazine Hcl | Promethazine Hcl | 151 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 148 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 33 |
| Vascepa | Icosapent Ethyl | 136 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 43 |
| Ondansetron Odt | Ondansetron | 131 | 43 |
| Eliquis | Apixaban | 129 | 27 |
| Meloxicam | Meloxicam | 129 | 33 |
| Simvastatin | Simvastatin | 128 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 126 | 33 |
| Sertraline Hcl | Sertraline Hcl | 120 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 25 |
| Ozempic | Semaglutide | 116 | 22 |
| Bupropion Xl | Bupropion Hcl | 110 | 27 |
| Eszopiclone | Eszopiclone | 106 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 22 |
| Estradiol | Estradiol | 99 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 24 |
| Doxepin Hcl | Doxepin Hcl | 97 | 24 |
| Allopurinol | Allopurinol | 92 | 25 |
| Linzess | Linaclotide | 91 | 23 |
| Methocarbamol | Methocarbamol | 89 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 17 |
| Topiramate | Topiramate | 87 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 85 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 83 | 25 |
| Meclizine Hcl | Meclizine Hcl | 82 | 18 |
| Mometasone Furoate | Mometasone Furoate | 82 | suppressed |
| Atenolol | Atenolol | 77 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 23 |
| Mirtazapine | Mirtazapine | 73 | 17 |
| Levofloxacin | Levofloxacin | 72 | 59 |
| Methadone Hcl | Methadone Hcl | 70 | suppressed |
| Trulicity | Dulaglutide | 66 | 14 |
| Azithromycin | Azithromycin | 63 | 57 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 14 |
| Famotidine | Famotidine | 62 | 15 |
| Cefdinir | Cefdinir | 60 | 53 |
| Farxiga | Dapagliflozin Propanediol | 59 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | 11 |
| Alendronate Sodium | Alendronate Sodium | 56 | 12 |
| Carvedilol | Carvedilol | 56 | 18 |
| Chlorthalidone | Chlorthalidone | 56 | 12 |
| Naloxone Hcl | Naloxone Hcl | 56 | 53 |
| Temazepam | Temazepam | 55 | suppressed |
| Fluocinonide | Fluocinonide | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 13 |
| Diazepam | Diazepam | 50 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 15 |
| Brilinta | Ticagrelor | 47 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Xarelto | Rivaroxaban | 45 | 11 |
| Finasteride | Finasteride | 44 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 38 |
| Trintellix | Vortioxetine Hydrobromide | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | 14 |
| Risperidone | Risperidone | 40 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Armodafinil | Armodafinil | 38 | suppressed |
| Dutasteride | Dutasteride | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 32 | 11 |
| Progesterone | Progesterone, Micronized | 32 | suppressed |
| Anastrozole | Anastrozole | 31 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 31 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 26 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Relistor | Methylnaltrexone Bromide | 26 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 21 |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | 11 |
| Roflumilast | Roflumilast | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,938.85 · 113 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, DALVANCE, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FARXIGA, JOURNAVX, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, Quviviq, RELISTOR, REPATHA, REXULTI, Sunosi, TRINTELLIX, TRULANCE, TWIIST, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error